A website to provide support for people who have or have had any type of cancer, for their caregivers and for their family members.
Results 1 to 3 of 3

Thread: JAMA Abstract of Results from a Saw Palmetto Trial

  1. #1
    Top User pbj11's Avatar
    Join Date
    May 2007
    Posts
    6,595

    JAMA Abstract of Results from a Saw Palmetto Trial

    JAMA. 2011;306(12):1344-1351. doi: 10.1001/jama.2011.1364
    Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract Symptoms

    A Randomized Trial
    Michael J. Barry, MD; Sreelatha Meleth, PhD; Jeannette Y. Lee, PhD; Karl J. Kreder, MD, MBA; Andrew L. Avins, MD, MPH; J. Curtis Nickel, MD; Claus G. Roehrborn, MD; E. David Crawford, MD; Harris E. Foster, Jr, MD; Steven A. Kaplan, MD; Andrew McCullough, MD; Gerald L. Andriole, MD; Michael J. Naslund, MD; O. Dale Williams, PhD; John W. Kusek, PhD; Catherine M. Meyers, MD; Joseph M. Betz, PhD; Alan Cantor, PhD; Kevin T. McVary, MD for the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study GroupAuthor Affiliations

    • Author Affiliations: Department of Medicine, Massachusetts General Hospital, Boston (Dr Barry); Division of Preventive Medicine, University of Alabama, Birmingham (Drs Meleth, Williams, and Cantor); Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock (Dr Lee); Department of Urology, University of Iowa, Iowa City (Dr Kreder); Division of Research, Northern California Kaiser Permanente, Oakland (Dr Avins); Department of Urology, Queen's University, Kingston, Ontario, Canada (Dr Nickel); Department of Urology, University of Texas Southwestern Medical Center, Dallas (Dr Roehrborn); Section of Urologic Oncology, University of Colorado, Denver (Dr Crawford); Section of Urology, Yale University School of Medicine, New Haven, Connecticut (Dr Foster); Department of Urology, Weill Cornell Medical College, New York, New York (Dr Kaplan); Urology Associates, New York University, New York, New York (Dr McCullough); Division of Urologic Surgery, Washington University School of Medicine, St Louis, Missouri (Dr Andriole); Maryland Prostate Center, University of Maryland, Baltimore (Dr Naslund); National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland (Dr Kusek); National Center for Complementary and Alternative Medicine, Bethesda, Maryland (Dr Meyers); National Institutes of Health Office of Dietary Supplements, Bethesda, Maryland (Dr Betz); and Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Dr McVary).


    Abstract

    Context Saw palmetto fruit extracts are widely used for treating lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH); however, recent clinical trials have questioned their efficacy, at least at standard doses (320 mg/d).
    Objective To determine the effect of saw palmetto extract (Serenoa repens, from saw palmetto berries) at up to 3 times the standard dose on lower urinary tract symptoms attributed to BPH.
    Design, Setting, and Participants A double-blind, multicenter, placebo-controlled randomized trial at 11 North American clinical sites conducted between June 5, 2008, and October 10, 2010, of 369 men aged 45 years or older, with a peak urinary flow rate of at least 4 mL/s, an American Urological Association Symptom Index (AUASI) score of between 8 and 24 at 2 screening visits, and no exclusions.
    Interventions One, 2, and then 3 doses (320 mg/d) of saw palmetto extract or placebo, with dose increases at 24 and 48 weeks.
    Main Outcome Measures Difference in AUASI score between baseline and 72 weeks. Secondary outcomes included measures of urinary bother, nocturia, peak uroflow, postvoid residual volume, prostate-specific antigen level, participants' global assessments, and indices of sexual function, continence, sleep quality, and prostatitis symptoms.
    Results Between baseline and 72 weeks, mean AUASI scores decreased from 14.42 to 12.22 points (−2.20 points; 95% CI, −3.04 to −0.36) with saw palmetto extract and from 14.69 to 11.70 points (−2.99 points; 95% CI, −3.81 to −2.17) with placebo. The group mean difference in AUASI score change from baseline to 72 weeks between the saw palmetto extract and placebo groups was 0.79 points favoring placebo (upper bound of the 1-sided 95% CI most favorable to saw palmetto extract was 1.77 points, 1-sided P = .91). Saw palmetto extract was no more effective than placebo for any secondary outcome. No clearly attributable adverse effects were identified.
    Conclusion Increasing doses of a saw palmetto fruit extract did not reduce lower urinary tract symptoms more than placebo.
    Trial Registration clinicaltrials.gov Identifier: NCT00603304
    Last edited by pbj11; 12-30-2011 at 06:10 PM.

  2. #2
    Banned New User
    Join Date
    Jul 2019
    Posts
    1
    Sure saw palmetto doesn't work. But ask yourself, what are the active chemicals, what is the mechanism of action. Then, upon what pathway, and why it fails. Then once you understand that, then you may discover that it might have a secondary use, or as you understand it now-you actually have a grasp - what alterations or combination might cause a useful action.
    Last edited by po18guy; 07-22-2019 at 03:19 AM. Reason: charity.

  3. #3
    Super Moderator Top User po18guy's Avatar
    Join Date
    Feb 2012
    Posts
    10,486
    Quote Originally Posted by degarb View Post
    Sure saw palmetto doesn't work.
    Do you have a connection to a cancer, either by diagnosis or as a caregiver?
    05/08-07/08 Tumor appears behind left ear. Followed by serial medical incompetence on the parts of PCP, veteran oncologist and pathologist (misdiagnosis via non-diagnosis). Providential guidance to proper care at an NCI designated comprehensive cancer center.
    07/08 Age 56 DX 1) Peripheral T-Cell Lymphoma-Not Otherwise Specified. Stage IV-B, >50 ("innumerable") tumors, bone marrow involvement.
    08/08-12/08 Four cycles CHOEP14 + four cycles GND (Cyclofosfamide, Doxorubicin, Vincristine, Etoposide, Prednisone & Gemcitabine, Navelbine, Doxil)
    02/09 2) Relapse.
    03/09-06/13 Clinical trial of Romidepsin > long-term study. NED for 64 twenty-eight day cycles, dose tapered.
    07/13 3) Relapse, 4) Suspected Mutation.
    08/13-02/14 Romidepsin increased, stopped for lack of response. Watch & Wait.
    09/14 Relapse/Progression. Visible cervical nodes appear within 4 days of being checked clear.
    10/06/14 One cycle Belinostat. Discontinued to enter second clinical trial.
    10/25/14 Clinical trial of Alisertib/Failed - Progression.
    01/12/15 Belinostat resumed/Failed - Progression. 02/23/15
    02/24/15 Pralatrexate/Failed - Progression. 04/17/15
    04/15 Genomic profiling reveals mutation into PTCL-NOS + AngioImmunoblastic T-Cell Lymphoma. Stage IV-B a second time. Two dozen tumors + small intestine (Ileum) involvement.
    04/22/15 TEC (Bendamustine, Etoposide, Carboplatin). Full response in two cycles. PET/CT both clear. Third cycle followed.
    06/15-07/15 Transplant preparation (X-rays, spinal taps, BMB, blood test, MUGA scan, lung function, CMV screening, C-Diff testing etc. etc. etc.) Intrathecal Methotrexate during spinal tap.
    BMB reveals 5) 26% blast cells of 20q Deletion Myelodysplastic Syndrome MDS), a bone marrow cancer and precursor to Acute Myeloid Leukemia.
    07/11-12/15 Cyclofosfamide + Fludarabine conditioning regimen.
    07/16/15 Total Body Irradiation.
    07/17/15 Moderate intensity Haploidentical Allogeneic Stem Cell Transplant receiving my son's peripheral blood stem cells.
    07/21-22/15 Triple dose Cyclofosfamide + Mesna, followed by immunosuppressants Tacrolimus and Mycophenolate Mofetil.
    07/23-08/03/15 Marrow producing zero blood cells. Fever. Hospitalized two weeks.
    08/04/15 Engraftment occurs, and blood cells are measurable - released from hospital.
    08/13/15 Day 26 - Marrow is 100% donor cells. Platelets climbing steadily, red cells follow.
    09/21/15 Acute skin Graft versus Host Disease arrives.
    DEXA scan reveals Osteoporosis.
    09/26/-11/03/15 Prednisone to control skin GvHD.
    11/2015 Acute GvHD re-classified to Chronic Graft versus Host Disease.
    05/2016 Tacrolimus stopped. Prednisone from 30-90mg daily tried. Sirolimus begun. Narrow-band UV-B therapy started, but discontinued for lack of response. One treatment of P-UVAreceived, but halted due to medication reaction.
    09/16/16 Three skin punch biopsies.
    11/04/16 GvHD clinical trial of Ofatumumab (Arzerra) + Prednisone + Methylprednisolone begun.
    12/16 Type II Diabetes, Hypertension - both treatment-related.
    05/17 Extracorporeal Photopheresis (ECP) begun in attempt to control chronic Graft-versus-Host-Disease (cGvHD. 8 year old Power Port removed and replaced with Vortex (Smart) Port for ECP.
    05/2017 Chronic anemia (low hematocrit). Chronic kidney disease. Cataracts from radiation and steroids.
    06/17 Trying various antibiotics in a search for tolerable prophylaxis.
    08/17 Bone marrow biopsy reveals the presence of 2% cells with 20q Deletion Myelodysplastic Syndrome, considered to be Minimum Residual Disease.
    12/17 Bone marrow biopsy reveals no abnormalities in the marrow - MDS eradicated. The steroid taper continues.
    01/18 Consented for Kadmon clinical trial.
    03/18 Began 400mg daily of KD025, a rho-Associated Coiled-coil Kinase 2 Inhibitor (ROCK2).
    09/18 Due to refractory GvHD, Extracorporeal Photopheresis halted after 15 months ue to lack of additional benefit.
    10/18 I was withdrawn from the Kadmon KD025 clinical trial due to increasing fatigue/lack of benefit.
    11/18 Began therapy with Ruxolitinib (Jakafi), a JAK 1&2 inhibitor class drug. Started at half-dose due to concerns with drug interactions.

    To date: 1 cancer, relapse, second relapse/mutation into 2 cancers, then 3 cancers simultaneously, 20 chemotherapy/GVHD drugs in 11 regimens (4 of them at least twice), 5 salvage regimens, 4 clinical trials, 5 post-transplant immuno-suppressant/modulatory drugs, the equivalent of 1,000 years of background radiation from 40+ CT series scans and about 24 PET scans.
    Both lymphoid and myeloid malignancies lend a certain symmetry to the hematological journey.

    Believing in the redemptive value of suffering makes all the difference.

 

Similar Threads

  1. First results from IMA950 trial
    By NikosF in forum Brain Tumors Forum
    Replies: 2
    Last Post: 12-01-2012, 01:06 PM
  2. TH-302 Trial Results
    By lancepeace in forum Pancreatic Cancer Forum
    Replies: 0
    Last Post: 02-21-2012, 02:08 PM
  3. regorafenib Phase III trial Results
    By lancepeace in forum Colon Cancer and Rectal Cancer Forum
    Replies: 1
    Last Post: 01-19-2012, 01:00 AM
  4. Metastatic Melanoma PV-10 Trial Results Encouraging
    By HaoleBoy in forum Melanoma and Skin Cancer Forum
    Replies: 0
    Last Post: 10-28-2009, 12:39 AM
  5. horrifying trial results for 2nd generation Ablatherm
    By Replicant in forum Prostate Cancer Forum
    Replies: 5
    Last Post: 04-02-2009, 09:10 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •